January 4, 2024

BioDigit IBM Study | Remote Gait Assessment in PSP/PD Publication

Happy New Year!

In our first 2024 update, I am thrilled to share that our team has recently started the BioDigit IBM clinical study, formed a new partnership with the Myositis Support & Understanding, and published a paper in BMC Neurology. 

BioDigit IBM is a pilot natural history study focused on developing sensor-based biomarkers for inclusion body myositis (IBM). The study aims to collect longitudinal clinical and wearable sensor data using PAMSysTM and PAMSys ULMTM sensors for precision actigraphy and monitoring upper limb function during activities of daily living. 

The clinical study is in collaboration with Mazen Dimachkie, MD at the University of Kansas Medical Center and the Myositis Support & Understanding. Recruitment for BioDigit IBM commenced in December 2023, and the study is set to complete its recruitment before the end of this month. 

Also, I am excited to share a recent paper from our digital biomarker study in frontotemporal lobar degeneration (FTLD) (ClinicalTrials.gov NCT05956834), published in BMC Neurology.

The paper, titled "Remote at-home wearable-based gait assessments in Progressive Supranuclear Palsy compared to Parkinson’s Disease" showcases the use of LEGSysTM for at-home gait assessment in progressive supranuclear palsy (PSP) - a severe and rapidly progressive FTLD syndrome - and Parkinson's disease. 

If you are interested in obtaining copies of our published papers, posters, and abstracts, or exploring potential collaboration and partnership opportunities, please contact us.

About BioSensics: BioSensics is the leader in developing wearable sensors and digital health technologies for clinical trials and research, remote patient monitoring, and health assessments. Founded in 2007 by three scientists from Harvard, BioSensics has created new paradigms in using wearable sensors in healthcare and revolutionized the medical alert industry by creating technologies that are now used by thousands of older adults.

BioSensics is the only company that offers comprehensive end-to-end solutions and services for the acquisition of digital measures and biomarkers in clinical trials and research. BioSensics designs and validates all elements of their solutions, including wearable sensors, software, and algorithms. Our experienced research team extends complete scientific and technical consultation services, such as study design and protocol development, in addition to statistical analysis. Furthermore, BioSensics clinical operations team provides comprehensive operational and logistics support for clinical trial projects.

BioSensics has received over $50M in research and development program support from the U.S. National Institute of Health (NIH). In 2022, BioSensics was chosen by NIH to create remote measurement technologies for use in clinical trials involving people with rare diseases.